



## Effects of Drugs on Ion Channels

Guest Editors:

### **Dr. Ferenc Papp**

Department of Biophysics and  
Cell Biology, Faculty of Medicine,  
University of Debrecen, Egyetem-  
ter 1, H-4032 Debrecen, Hungary

### **Dr. Tibor Gabor Szántó**

Department of Biophysics and  
Cell Biology, Faculty of Medicine,  
University of Debrecen, Egyetem-  
ter 1, H-4032 Debrecen, Hungary

Deadline for manuscript  
submissions:

**closed (30 December 2023)**

### **Message from the Guest Editors**

Dear Colleagues,

You are invited to submit original articles that demonstrate the effects of new molecules on ion channels or describe the mechanism of action of known molecules (small molecule compounds as well as peptides) that have yet to be clarified. We also welcome submissions of review articles that summarize the current state of knowledge and help researchers to navigate this field.

Many ion channel mutations have been associated with diseases such as LQT syndrome, Brugada syndrome, epilepsy, etc., which are called channelopathies. For this reason, one of the most important ultimate goals of ion channel modulator research is to find molecules that may be potential drug candidates, either acting as an inhibitor or as an activator. On the other hand, understanding the factors that regulate gating transitions of ion channels may aid the design of more efficacious drugs with state-dependent binding. Consequently, studies of the drug–ion channel interactions in channels that display inactivation are also necessary and relevant.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)